Selected Publications
A) Research Papers
1. Ouimet M, Koster S, Sakowski E, Ramkhelawon B, van Solingen C, Oldebeken S, Karunakaran D, Portal-Celhay C, Sheedy FJ, Ray TD, Cecchini K, Zamore PD, Rayner KJ, Marcel YL, Philips JA, Moore KJ. “Mycobacterium tuberculosis induces the miR-33 locus to reprogram autophagy and host lipid metabolism.” Nat Immunol. 2016. (6):677-86.
2. Ní Cheallaigh C, Sheedy FJ, Harris J, Coleman MM, Lee J, West K, Martinez-Gutierrez N, Hearnden C, Tynan G, Carroll E, Jones SA, Corr SC, Bernard N, Kornfeld H, Doug Golenbock DG, Gordon S, O'Neill LA, Lavelle EC & Keane J. “A common variant in Mal regulates interferon gamma signaling and increases susceptibility to Mycobacterium tuberculosis.” Immunity 2016, 44(2):368-79.
3. Gleeson LE, Sheedy FJ, Palsson-McDermott EM, O’Leary S, O’Sullivan MP, O'Neill LA, Keane J. Mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication.” J Immunol 2016, 96(6):2444-9.
4. Ouimet M, Ediriweera H Gundra UM, Sheedy FJ, Ramkhelawon B, Hutchison S, Rinehold K van Solingen C, Fullerton M, Cecchini K, Rayner KJ, Steinberg G, Zamore P, Fisher EA, Loke P, Moore KJ. “Metabolic regulation by miR-33 in macrophages controls immune effector responses.” J Clin Invest 2015, 125(12):4434-4348.
5. Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, van den Bosch MW, Quinn SR, Domingo-Fernandez R, Johnson DG, Jiang JK, Israelsen WJ, Keane J, Thomas C, Clish C, Vanden Heiden M, Xavier RJ, O'Neill LA. “Pyruvate Kinase M2 Regulates Hif-1α Activity and IL-1β Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages.” Cell Metab. 2015, 21(1):65-80.
6. Ramkhelawon B, Hennessy EJ, Menager M, Ray TD, Sheedy FJ, Hutchinson S, Wanschel A, Oldebeken S, Geoffrion M, Spiro W, Miller G, McPherson R, Rayner KJ, Moore KJ. “Netrin-1 promotes macrophage accumulation and insulin resistance in obesity.” Nat. Med 2014, 20(4);377-385.
7. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DG, Stuart LM, Latz E, Fitzgerald KA, Moore KJ. “CD36 coordinates NLRP3 inflammasome activation by facilitating the intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation”. Nat Immunol 2013, 14(8):812-820.
8. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X, Khatsenko OG, Kaimal V, Lees CJ, Fernandez-Hernando C, Fisher EA, Temel RE, Moore KJ. “Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.” Nature 2011, 478(7369):404-7.
9. Durrani O, Banahan K, Sheedy FJ, McBride L, Ben-Chetrit E, Greiner K, Vaughan RW, Kondeatis E, Hamburger J, Fortune F, Stanford MR, Murray PI, O'Neill LA, Wallace GR. “TIRAP Ser180Leu polymorphism is associated with Behcet's disease.” Rheumatology (Oxford) 2011, 50(10):1760-5.
10. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, Fernandez-Hernando C, Fisher EA, Moore KJ. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011, 121(7):2921-31.
11. Hennessy EJ, Sheedy FJ, Santamaria D, Barbacid M, O'Neill LA. Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6. J Biol Chem 2011, 286(29):25531-9.
12. McCoy CE, Sheedy FJ, Qualls JE, Doyle SL, Quinn SR, Murray PJ, O'Neill LA. IL-10 inhibits miR-155 induction by Toll-like receptors. J Biol Chem. 2010, 2;285(27):20492-8.
13. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q, Johnson DS, Chen Y, O'Neill LA. Negative regulation of Toll-like receptor-4 via the targeting of PDCD4 by miR-21. Nat. Immunol 2010 11(2):141-147.
14. Sheedy FJ, Marinou I, O'Neill LA, Wilson AG. “The Mal/TIRAP S180L and TLR4 G299D polymorphisms are not associated with susceptibility to, or severity of, rheumatoid arthritis”. Ann Rheum Dis. 2008; 67(9):1328-31.
B) Review Articles
15. Gleeson LE & Sheedy FJ, “Metabolic reprogramming & inflammation: Fuelling the host response to pathogens.” Semin Immunol. 2016. pii: S1044-5323(16)30108-7.
16. Sheedy FJ, “Turning 21: Induction of miR-21 as a key switch in the inflammatory response” Front Immunol 2015, 6(00019).
17. Sheedy FJ & Moore KJ. “IL-1 signaling in atherosclerosis: sibling rivalry. Nat Immunol 2013, 14;1030-1032.
18. Moore KJ, Sheedy FJ, Fisher EA. “Macrophages in atherosclerosis: a dynamic balance.” Nat Rev Immunol 2013, 13(10):709-21.
19. O’Neill LA, Sheedy FJ, McCoy CE. “MicroRNAs: the fine-tuners of Toll-like receptor signaling.” Nat Rev Immunol. 2011, 11(3):163-75.
20. Sheedy FJ & O’Neill LA. “Adding fuel to fire: microRNAs as a new class of mediators of inflammation”. Ann Rheum Dis. 2008; 67 Suppl 3:iii50-55.
21. Sheedy FJ & O'Neill LA. “The Troll in Toll: Mal and Tram as bridges for TLR2 and TLR4 signaling.” J Leukoc Biol. 2007; 82(2):196-203.
C) Published patents (1)
22. Fernandez-Hernando C, Moore KJ, Rayner KJ, Sheedy FJ, Suarez Y. “miR-33 inhibitors and uses thereof to decrease inflammation.” WO Patent App. PCT/US2012/035855